HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Willmore, L. J. Articles by Villarreal, H. J. Search for Related Content PubMed PubMed Citation Articles by Willmore, L. J. Articles by Villarreal, H. J.

Effect of valproic acid on hepatic function

Neurology Service. Veterans Administration Hospital, and the Department of Neurology. University of Florida College of Medicine, Gainesville, Florida.

Altered hepatic function tests occurred in four of 25 patients treated with valproic acid. An average dose reduction in three patients of 10 mg per kilogram per day resulted in reversion of serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) to normal. The drug was discontinued in one patient. Careful monitoring of hepatic function is required of patients being treated with valproic acid, but our experience suggests that dose reduction alone may be effective in preventing untoward hepatic side effects.

Dr. Willmore's address is Neurology Service I 1'271, Veterans Administration Hospital, Gainesville, FL 32602.

Supported by the Medical Research Service of the Veterans Administration and the Epilepsy Research Foundation of Florida, Inc. Dr. Bruni is sponsored by the Ministry of Health, Ontario, Canada; Dr. Villarreal is sponsored by ANUIES, Mexico, and the Epilepsy Research Foundation of Florida, Inc.

Accepted for publication May 17, 1978.

This article has been cited by other articles:

				R. Selby, E. Nisbet-Brown, R. K. Basran, L. Chang, and N. F. Olivieri Valproic Acid and Augmentation of Fetal Hemoglobin in Individuals With and Without Sickle Cell Disease Blood, July 15, 1997; 90(2): 891 - 892. [Full Text] [PDF]

				D. L. Coulter Carnitine Deficiency in Epilepsy: Risk Factors and Treatment J Child Neurol, November 1, 1995; 10(2_suppl): 2S32 - 2S39. [Abstract] [PDF]

				L. J. Willmore, W. J. Triggs, and J. M. Pellock Valproate Toxicity: Risk-Screening Strategies J Child Neurol, January 1, 1991; 6(1): 3 - 6. [PDF]

				D. L. Coulter Review Article: Carnitine, Valproate, and Toxicity J Child Neurol, January 1, 1991; 6(1): 7 - 14. [Abstract] [PDF]